Gilead Sciences: Exec Insiders and Funds Cashing Stock in Q3

Insiders are generally long-term investors due to restriction in making short-term profits. In contrast, wealth management institutions always have short-term investment. Wall St. Watchdog reveals information regarding the insiders and institutions which recently decreased stock shares of Gilead Sciences Inc. (NASDAQ:GILD).

SEC data indicate these insiders have sold Gilead Sciences Inc.’s stock since 06/30/2011:

  • Martin John C: act as Chairman and CEO. On 07/01/2011, sold 92,320 shares, worth $3,855,300.
  • Martin John C: act as Chairman and CEO. On 08/01/2011, sold 92,320 shares, worth $3,851,600.
  • Martin John C: act as Chairman and CEO. On 11/01/2011, sold 92,320 shares, worth $3,789,700.
  • Martin John C: act as Chairman and CEO. On 09/01/2011, sold 92,320 shares, worth $3,699,300.
  • Martin John C: act as Chairman and CEO. On 10/10/2011, sold 92,320 shares, worth $3,692,800.

SEC data indicate that these institutions significantly reduced their stock shares of Gilead Sciences Inc. in Q3 2011:

  • MAVERICK CAPITAL LTD: On 06/30/2011, held 3,278,333 shares, worth $135,755,770. On 09/30/2011, held 0 shares.
  • RENAISSANCE GROUP LLC: On 06/30/2011, held 1,267,968 shares, worth $52,506,555. On 09/30/2011, held 0 shares.
  • PARTNER FUND MANAGEMENT, L.P.: On 06/30/2011, held 1,210,774 shares, worth $50,138,151. On 09/30/2011, held 0 shares.
  • HEALTHCOR GROUP, LLC: On 06/30/2011, held 1,000,000 shares, worth $41,410,000. On 09/30/2011, held 0 shares.
  • HEALTHCOR MANAGEMENT, L.P.: On 06/30/2011, held 1,000,000 shares, worth $41,410,000. On 09/30/2011, held 0 shares.

About the company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Competitors to Watch: Roche Holding Ltd. (RHHBY), GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Bristol Myers Squibb Co. (NYSE:BMY), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Trimeris, Inc. (NASDAQ:TRMS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Hemispherx BioPharma, Inc (AMEX:HEB).

(Note: Data regarding Gilead Sciences Inc.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>